83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Robert Huddart(Institute of Cancer Research), Lumarie Santiago(Nektar Therapeutics (United States)), Yohann Loriot(Institut Gustave Roussy), Ute Hoch(University of Arizona), Jiřı́ Novotný(Charles University), Ananya Choudhury(University of Manchester), David Chien(Nektar Therapeutics (United States)), Mehmet Asım Bilen(Emory Healthcare), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), D.C. Cho(NYU Langone Health), Mary Tagliaferri(Nektar Therapeutics (United States)), Arjun Vasant Balar(NYU Langone Health), Dechen Yu(Nektar Therapeutics (United States)), Sue Currie(St. Paul's Hospital), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k